Plasma Pharmacokinetics of Idarubicin and its 13-Hydroxymetabolite after Intravenous and Oral Administration under Fasting and Non-Fasting Conditions

References

• Crooke S T. A review of carminomycin–a new anthracycline developed in the USSR. J Med 1977; 8: 295–316
   PubMedGoogle Scholar
• Berman E, Wittes R E, Leyland-Jones B, et al. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Res 1983; 43: 6096–101
   PubMed Web of Science ®Google Scholar
• Daghestani A N, Arlin Z A, Leyland-Jones B, et al. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (Idarubicin) in adult patients with acute leukemia. Cancer Res 1985; 45: 1408–12
   PubMed Web of Science ®Google Scholar
• Carella A M, Santini G, Martinengo M, et al. 4-demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias: a pilot study. Cancer 1985; 55: 1452–4
   PubMed Web of Science ®Google Scholar
• Ganzina F, Pacciarini M A, Di Pietro N. Idarubicin (4-demethoxydaunorubicin): a preliminary overview of clinical and preclinical studies. Invest New Drug 1986; 4: 85–105
   PubMed Web of Science ®Google Scholar
• Casazza A M. Experimental evaluation of anthracycline analogs. Cancer Treat Rep 1979; 63: 835–44
   PubMedGoogle Scholar
• Casazza A M, Bertazzoli C, Pratesi G, et al. Antileukemic activity and cardiac toxicity of 4-demethoxydaunorubicin in mice (Abstract). Proc Am Assoc Cancer Res 1979; 63: 1
   Google Scholar
• May P M, Williams G K, Williams D R. Specification studies of Adriamycin, Quelamycin and their metal complexes. Inorgancia Chimica Acta 1980; 46: 221–8
   Web of Science ®Google Scholar
• Dodion P, Sanders C, Rombaut W, et al. Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxydaunorubicinol against human normal myeloid stem cells and human malignant cells in vitro. Eur J Cancer Clin Oncol 1987; 23: 1909–14
   PubMedGoogle Scholar
• Casazza A M, Barbieri B, Fumagalli A, Geroni M C. Biologic activity of 4-demethoxy-13-dihydrodaunorubicin. Proc Am Assoc Cancer Res 1983; 24: 25
   Google Scholar
• Melander A, Danielson K, Hanson A, et al. Enhancement of hydralazine bioavailability by food. Clin Pharmacol Ther 1977; 22: 104–7
   PubMed Web of Science ®Google Scholar
• Eksborg S, Nilsson B. Reversed-phase liquid chromatographic determination of Idarubicin and its 13-hydroxymetabolite in human plasma. J Chromatogr 1989; 488: 427–34
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Perrier D. Pharmacokinetics. Marcel Dekker, Inc, New York 1982
   Google Scholar
• Gillies H C, Herriott D, Liang R, et al. Pharmacokinetics of Idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. Br J Clin Pharmacol 1987; 23: 303–10
   PubMed Web of Science ®Google Scholar
• Smith D B, Margison J M, Lucas S B, et al. Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin. Cancer Chemother Pharmacol 1987; 19: 138–42
   PubMed Web of Science ®Google Scholar
• Eksborg S, Strandler H S, Edsmyr F, et al. Pharmacokinetic study of i.v. infusions of adriamycin. Eur J Clin Pharmacol 1985; 28: 205–12
   PubMed Web of Science ®Google Scholar
• Eksborg S, Stendahl U, Lönroth U. Comparative pharmacokinetic study of adriamycin and 4′epi-adriamycin after their simultaneous intravenous administration. Eur J Clin Pharm 1986; 30: 629–31
   PubMed Web of Science ®Google Scholar
• Welling P G. Interactions affecting drug absorption. Clin Pharmacokinet 1984; 9: 404–34
   PubMed Web of Science ®Google Scholar
• Andersson B, Andersson I, Beran M, et al. Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex. Cancer Chemother Pharmacol 1979; 2: 15–7
   PubMed Web of Science ®Google Scholar
• Greene W, Huffman D WPH, Schimpff S, et al. High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity. Cancer 1972; 30: 1419–27
   PubMed Web of Science ®Google Scholar
• Plezia P M, Alberts D S, McCloskey T, Peng Y M. Oral Idarubicin (I): Evaluation of food effects and consistency of adsorption. Clin Pharmacol Ther 1988; 43: 16
   PubMed Web of Science ®Google Scholar
• Elbæk K, Ebbehøj E, Jakobsen A, et al. Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side-effects. Clin Pharmacol Ther 1989; 45: 627–34
   PubMed Web of Science ®Google Scholar